ReviewDermatologic therapy
New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
Review in Dermatologic therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Pooled it
- Pharmacokinetics, pharmacodynamics and safety of the inverse retinoic acid-related orphan receptor γ agonist AZD0284.British journal of clinical pharmacology · 2020Trial
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.The British journal of dermatology · 2019Trial
- Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic.International journal of dermatology · 2026Article
- Chronic Hyperplastic Candidiasis-An Adverse Event of Secukinumab in the Oral Cavity: A Case Report and Literature Review.Diseases (Basel, Switzerland) · 2025Article
- Article
- Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management.Mycology · 2024Review
- Review
- Article
- OralDiagnostics (Basel, Switzerland) · 2021Article
- Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile.Frontiers in pharmacology · 2020Article
- The pathological role of Wnt5a in psoriasis and psoriatic arthritis.Journal of cellular and molecular medicine · 2019Review
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.Clinical reviews in allergy & immunology · 2018Review
- Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report.Dermatology and therapy · 2018Article
- The role of IL-23 and the IL-23/TJournal of the European Academy of Dermatology and Venereology : JEADV · 2017Review
- CD1b-autoreactive T cells contribute to hyperlipidemia-induced skin inflammation in mice.The Journal of clinical investigation · 2017Article
- Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.Therapeutics and clinical risk management · 2017Review
- Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.Journal of gastrointestinal cancer · 2016Article
- Review
- Targeting IL-23 in psoriasis: current perspectives.Psoriasis (Auckland, N.Z.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of effective and well-tolerated biologic therapies has advanced the management of psoriasis by enabling clinicians to treat underlying disease mechanisms. Biologics approved for the treatment of moderate-to-severe psoriasis include three tumor necrosis factor alpha inhibitors and an interleukin-12/interleukin-23 inhibitor. The establishment of the immunological basis of psoriasis has led to the development of biologic agents targeting specific downstream mediators in the psoriatic cascade. These drugs inhibit cytokines and cytokine signaling/transcription mediators like interleukin-17, which plays an important role in immunopathogenesis. Several interleukin-17 inhibitors are undergoing phase 3 clinical studies. In addition, biologics that selectively inhibit interleukin-23 have been assessed in phase 2 studies. This review describes how the dissection of pathways in the immunopathogenesis of psoriasis has led to the development of therapeutic agents and highlights the latest clinical efficacy, safety and tolerability data on new and emerging biologic therapies that selectively target interleukin-17 or interleukin-23.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.